Physician profile
Patrick Paul Branagan
NPI 1669799441
$9,049.13
in general payments reported to CMS, 2019-2025
9 companies · $590 in 2025
The $590 reported for 2025 was more than what 76% of Primary Podiatric Medicine providers received nationally (typical 2025 total: $232).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,647 · 2020: $172 · 2021: $153 · 2022: $6,343 · 2023: $116 · 2024: $29.30 · 2025: $590.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $735.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $734.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pylant Medical | $6,187.77 | 2019-2024 | |
| Arthrex, INC. | $1,395.20 | 2022 | |
| Smith+Nephew, INC. | $628.37 | 2019-2025 | Coblation |
| Stryker Corporation | $484.84 | 2019-2025 | Infinity Adaptis, Prostep Mica, Augment Injectable |
| Biotissue Holdings INC. | $130.18 | 2025 | |
| P Bar Medical LLC | $102.16 | 2025 | |
| Organogenesis INC. | $60.83 | 2019-2023 | Puraply |
| Integra Lifesciences Corporation | $45.09 | 2023 | Tenoglide |
| Kci USA, INC. | $14.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Branagan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.